Publications by Ana Slipicevic
36 publications found
Original articles
The one-carbon metabolic enzyme MTHFD2 promotes resection and homologous recombination after ionizing radiation
Mol Oncol (in press)
DOI 10.1002/1878-0261.13645, PubMed 38533616
Formate overflow drives toxic folate trapping in MTHFD1 inhibited cancer cells
Nat Metab, 5 (4), 642-659
DOI 10.1038/s42255-023-00771-5, PubMed 37012496
Growth Response and Differentiation of Bone Marrow-Derived Mesenchymal Stem/Stromal Cells in the Presence of Novel Multiple Myeloma Drug Melflufen
Cells, 11 (9)
DOI 10.3390/cells11091574, PubMed 35563880
The Peptide-Drug Conjugate Melflufen Modulates the Unfolded Protein Response of Multiple Myeloma and Amyloidogenic Plasma Cells and Induces Cell Death
Hemasphere, 6 (3), e687
DOI 10.1097/HS9.0000000000000687, PubMed 35243210
Novel Peptide-drug Conjugate Melflufen Efficiently Eradicates Bortezomib-resistant Multiple Myeloma Cells Including Tumor-initiating Myeloma Progenitor Cells
Hemasphere, 5 (7), e602
DOI 10.1097/HS9.0000000000000602, PubMed 34136753
Melphalan flufenamide inhibits osteoclastogenesis by suppressing proliferation of monocytes
Bone Rep, 15, 101098
DOI 10.1016/j.bonr.2021.101098, PubMed 34150958
Aminopeptidase Expression in Multiple Myeloma Associates with Disease Progression and Sensitivity to Melflufen
Cancers (Basel), 13 (7)
DOI 10.3390/cancers13071527, PubMed 33810334
MX2 mediates establishment of interferon response profile, regulates XAF1, and can sensitize melanoma cells to targeted therapy
Cancer Med, 10 (8), 2840-2854
DOI 10.1002/cam4.3846, PubMed 33734579
Targeting aggressive osteosarcoma with a peptidase-enhanced cytotoxic melphalan flufenamide
Ther Adv Med Oncol, 12, 1758835920937891
DOI 10.1177/1758835920937891, PubMed 32774473
Melflufen, a peptide-conjugated alkylator, is an efficient anti-neo-plastic drug in breast cancer cell lines
Cancer Med, 9 (18), 6726-6738
DOI 10.1002/cam4.3300, PubMed 32717133
MX 2 is a novel regulator of cell cycle in melanoma cells
Pigment Cell Melanoma Res, 33 (3), 446-457
DOI 10.1111/pcmr.12837, PubMed 31660681
Evaluation of CHK1 activation in vulvar squamous cell carcinoma and its potential as a therapeutic target in vitro
Cancer Med, 7 (8), 3955-3964
DOI 10.1002/cam4.1638, PubMed 29963769
Metabolic reprogramming is associated with flavopiridol resistance in prostate cancer DU145 cells
Sci Rep, 7 (1), 5081
DOI 10.1038/s41598-017-05086-6, PubMed 28698547
MiR-29a is a candidate biomarker of better survival in metastatic high-grade serous carcinoma
Hum Pathol, 54, 74-81
DOI 10.1016/j.humpath.2016.03.010, PubMed 27063471
Combined inhibition of the cell cycle related proteins Wee1 and Chk1/2 induces synergistic anti-cancer effect in melanoma
BMC Cancer, 15, 462
DOI 10.1186/s12885-015-1474-8, PubMed 26054341
Expression of CDK1(Tyr15), pCDK1(Thr161), Cyclin B1 (total) and pCyclin B1(Ser126) in vulvar squamous cell carcinoma and their relations with clinicopatological features and prognosis
PLoS One, 10 (4), e0121398
DOI 10.1371/journal.pone.0121398, PubMed 25849598
Cellular localization of CIP2A determines its prognostic impact in superficial spreading and nodular melanoma
Cancer Med, 4 (6), 903-13
DOI 10.1002/cam4.425, PubMed 25663244
Wnt5A promotes an adaptive, senescent-like stress response, while continuing to drive invasion in melanoma cells
Pigment Cell Melanoma Res, 28 (2), 184-95
DOI 10.1111/pcmr.12330, PubMed 25407936
Wee1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusions
Gynecol Oncol, 135 (1), 118-24
DOI 10.1016/j.ygyno.2014.07.102, PubMed 25093290
Isolation of melanoma cell subpopulations using negative selection
Methods Mol Biol, 1102, 501-12
DOI 10.1007/978-1-62703-727-3_26, PubMed 24258995
Low-dose anisomycin sensitizes melanoma cells to TRAIL induced apoptosis
Cancer Biol Ther, 14 (2), 146-54
DOI 10.4161/cbt.22953, PubMed 23192275
Cytoplasmic BRMS1 expression in malignant melanoma is associated with increased disease-free survival
BMC Cancer, 12, 73
DOI 10.1186/1471-2407-12-73, PubMed 22356677
High expression of Wee1 is associated with poor disease-free survival in malignant melanoma: potential for targeted therapy
PLoS One, 7 (6), e38254
DOI 10.1371/journal.pone.0038254, PubMed 22719872
Biological effects induced by insulin-like growth factor binding protein 3 (IGFBP-3) in malignant melanoma
Int J Cancer, 126 (2), 350-61
DOI 10.1002/ijc.24727, PubMed 19588500
Diagnostic and prognostic role of the insulin growth factor pathway members insulin-like growth factor-II and insulin-like growth factor binding protein-3 in serous effusions
Hum Pathol, 40 (4), 527-37
DOI 10.1016/j.humpath.2008.10.003, PubMed 19121847
Fli-1 expression in malignant melanoma
Histol Histopathol, 23 (11), 1309-14
DOI 10.14670/HH-23.1309, PubMed 18785112
The fatty acid binding protein 7 (FABP7) is involved in proliferation and invasion of melanoma cells
BMC Cancer, 8, 276
DOI 10.1186/1471-2407-8-276, PubMed 18826602
Expression and clinical role of DJ-1, a negative regulator of PTEN, in ovarian carcinoma
Hum Pathol, 39 (1), 87-95
DOI 10.1016/j.humpath.2007.05.014, PubMed 17949781
Pax-5 expression in nonhematopoietic tissues
Am J Clin Pathol, 126 (5), 798-804
DOI 10.1309/XEC7-JMW9-YRM7-4RNO, PubMed 17050077
Expression of activated Akt and PTEN in malignant melanomas: relationship with clinical outcome
Am J Clin Pathol, 124 (4), 528-36
DOI 10.1309/YT58WWMTA6YR1PRV, PubMed 16146807
Phorbol ester phorbol-12-myristate-13-acetate promotes anchorage-independent growth and survival of melanomas through MEK-independent activation of ERK1/2
Biochem Biophys Res Commun, 329 (1), 266-74
DOI 10.1016/j.bbrc.2005.01.143, PubMed 15721302
Review articles
Up-regulation of multidrug resistance protein MDR1/ABCB1 in carfilzomib-resistant multiple myeloma differentially affects efficacy of anti-myeloma drugs
Leuk Res, 101, 106499
DOI 10.1016/j.leukres.2020.106499, PubMed 33422770
Narrowing the knowledge gaps for melanoma
Ups J Med Sci, 117 (2), 237-43
DOI 10.3109/03009734.2012.658977, PubMed 22339359
Other articles
KIT in melanoma: many shades of gray
J Invest Dermatol, 135 (2), 337-338
DOI 10.1038/jid.2014.417, PubMed 25573046
Theses
Studies of the PI3K/Akt and MAPK/ERK1/2 signaling pathways: identification of novel downstream targets involved in development and progression of melanoma
In Series of dissertations submitted to the Faculty of Medicine, University of Oslo, Unipub, Oslo, no. 928, 1 b. (flere pag.)
BIBSYS 101119917, ISBN 978-82-8072-599-8
Signaling mechanisms involved in development and progression of malignant melanoma
A. Slipicevic, Oslo, 1 b. (flere pag.)
BIBSYS 050953427